Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Pictured: Facade of Moderna's building in Massachusetts

Patents

Moderna Wins UK Patent Battle Against Pfizer and BioNTech

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

August 1, 2025

2 min read

Dan Samorodnitsky

Earnings

Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.

August 1, 2025

4 min read

Annalee Armstrong

FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie

FDA

After Prasad’s Ouster, Makary Looks for Better Drug, Biologic Alignment at FDA

The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research into one entity.

August 1, 2025

2 min read

Tristan Manalac

Creative picture image collage banner of guy worker jump from financial charts determined company success.

Earnings

‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.

August 1, 2025

2 min read

Tristan Manalac

Layoffs

Merck’s $3B Savings Push Claims 6,000 Jobs

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth areas of its business.

August 1, 2025

1 min read

Tristan Manalac

President Donald Trump signs S.1852, The GENIUS Act, Friday, July 18, 2025, in the East Room of the White House. (Official White House Photo by Daniel Torok)

Drug pricing

Trump Asks Big Pharmas To Move on Most Favored Nation Drug Pricing—Or Else

In 17 identical letters posted to his Truth Social account, the president said companies must lower their prices or the government ‘will deploy every tool in our arsenal to protect American families from continued drug pricing practices.’

July 31, 2025

2 min read

Dan Samorodnitsky

Regulatory

FDA Issued Myeloma, Alzheimer’s Approvals in July but Rejected Two CGTs

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla. Meanwhile, the regulator turned away a cell therapy for Duchenne muscular dystrophy and a gene therapy for the rare disease Sanfilippo syndrome.

July 31, 2025

10 min read

Tristan Manalac

Problems and Challenges. Businessman stands on question mark

Earnings

Future of BMS’ Cobenfy Still in Limbo After Phase III Fail

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase III ARISE study, which earlier this year failed to demonstrate significant symptom improvement.

July 31, 2025

2 min read

Tristan Manalac